Cognitive Function and Quality of Life in Interferon Therapy for Melanoma
- 1 August 2000
- journal article
- clinical trial
- Published by SAGE Publications in Clinical Nursing Research
- Vol. 9 (3) , 352-363
- https://doi.org/10.1177/10547730022158537
Abstract
Although researchers have identified the presence of resident abuse within long-term care facilities, it has not come under the same scrutiny as have other aspects of abuse against older adults. This is due, in part, to the difficulty in defining the phenomenon. The purpose of this study was to articulate a definition of resident abuse as perceived by registered nurses working in long-term care institutions. Ethnoscience was the method used to answer this question. The five categories of resident abuse characteristics—perception of hurt felt by older residents, acts of omission or commission, context of care, intentional or unintentional, and behavioral clusters—that emerged through semistructured interviews and focus groups reflect the descriptions given by participants. Identifying a common definition of resident abuse suggests that assessment and intervention to reduce episodes of it are more likely to be effective.Keywords
This publication has 16 references indexed in Scilit:
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemiaNeurology, 1995
- Reversible cognitive decline during high-dose α-interferon treatmentPharmacology Biochemistry and Behavior, 1994
- The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.Journal of Clinical Oncology, 1993
- Cognitive functioning in cancer patientsNeurology, 1992
- Psychomotor Slowing Is Associated With Distal Symmetrical Polyneuropathy in Adults With Diabetes MellitusDiabetes, 1992
- Persistent neurotoxicity of systemically administered interferon‐alphaNeurology, 1991
- The Neuropsychiatric Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1987
- Central nervous system toxicity of interferonBritish Journal of Cancer, 1983
- Validity of the Trail Making Test as an Indicator of Organic Brain DamagePerceptual and Motor Skills, 1958